In gastric cancer, for example, where low expression of SIRT1 correlates with poor prognosis, SIRT1 activation was able to reverse chemoresistance and cancer stemness via the AMPK/FOXO3a pathway, indicating the potential use of SIRT1 activators as a novel therapeutic strategy in this cancer type [12]. This evidence concerns the gene SIRT1 and gastric cancer.